SU2C Scientific Research Teams
Robert I. Haddad, M.D.Scientific Research Team:
Robert I. Haddad, M.D.
Robert I. Haddad, M.D., is associate professor of medicine at Harvard Medical School, as well as chief of the Head and Neck Oncology Program and a member of the Department of Adult Oncology at Dana-Farber Cancer Institute, both in Boston, Mass.
Haddad received his medical degree from Saint Joseph University, French Faculty of Medicine in Beirut, Lebanon, and served as intern and resident at St. Luke’s Roosevelt Hospital Center in New York, N.Y. He completed his fellowship in hematology/oncology at Greenebaum Cancer Center, University of Maryland, in Baltimore, Md. Haddad is a member of several professional societies, including the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Society for Therapeutic Radiology and Oncology. He is a member of the National Comprehensive Cancer Network’s head and neck cancer guidelines committee and serves as co-chair of the thyroid cancer guidelines committee.
Haddad’s research has focused on the use of biologic agents and combined modality sequential and concurrent chemoradiotherapy in head and neck cancer. He was instrumental in the phase III study that led to FDA approval of docetaxel in head and neck cancer. His research interests also include the role of the human papillomavirus (HPV) as a cause of head and neck cancer, particularly the effect of such infection on treatment and prognosis, and the search for HPV-related biomarkers that can be useful for early detection, risk stratification, and detection of early relapse. He is particularly interested in the epidemiology of HPV infection as it relates to cancer risk in partners and spouses of patients with HPV-related cancers.
Haddad lectures extensively on head and neck cancer on the regional, national, and international level. He has authored more than 100 publications related to head and neck cancer.